Literature DB >> 12407041

Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone.

R A Anderson1, Z M Van Der Spuy, O A Dada, S K Tregoning, P M Zinn, O A Adeniji, T A Fakoya, K B Smith, D T Baird.   

Abstract

BACKGROUND: Suppression of spermatogenesis to azoospermia is required for effective hormonal male contraception, but the degree of suppression varies between ethnic groups. We here report the first study of hormonal suppression of spermatogenesis in two African centres using a regimen of oral progestogen with depot testosterone. METHODS A total of 31 healthy men (21 black) were recruited in Cape Town and 21 men in Sagamu, Nigeria. Subjects were randomized to take either 150 or 300 micro g desogestrel daily p.o. with testosterone pellets. In Cape Town, desogestrel was administered for 24 weeks with 400 mg testosterone re-administered 12 weekly. In Sagamu, desogestrel was administered for 52 weeks with 200 mg testosterone (later increased to 400 mg) re-administered 12-weekly.
RESULTS: In Cape Town, 22 men completed at least 20 weeks treatment. Azoospermia was achieved in 8/10 and 8/12 men in the 150 micro g and 300 micro g desogestrel groups. Four men in Sagamu withdrew. Azoospermia was achieved in all 17 men in the two groups. There were no significant changes in lipoprotein or haemoglobin concentrations in any group.
CONCLUSION: These data demonstrate that the combination of oral desogestrel with depot testosterone is an effective regimen for suppression of spermatogenesis in African as in Caucasian and Chinese men, with azoospermia achieved in a total of 83/98 (85%) men.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407041     DOI: 10.1093/humrep/17.11.2869

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Exploring older adolescents' and young adults' attitudes regarding male hormonal contraception: applications for clinical practice.

Authors:  Arik V Marcell; Keith Plowden; Shameeka M Bowman
Journal:  Hum Reprod       Date:  2005-07-08       Impact factor: 6.918

Review 2.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 3.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

4.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 5.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

6.  Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France.

Authors:  Jean-Claude Soufir
Journal:  Basic Clin Androl       Date:  2017-01-13

Review 7.  Male contraception.

Authors:  Jing Chao; Stephanie T Page; Richard A Anderson
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2014-06-05       Impact factor: 5.237

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.